EB ilə yaşayan insanlar üçün yeni bir ümid dövrü

Significant momentum is building in the search for better treatments, and ultimately a cure, for epidermoliz büllozası (EB), according to two recent articles published in The Pharmaceutical Journal. Together, they paint a picture of scientific progress, regulatory reform and renewed hope for the EB community.

A major feature exploring Is a cure for epidermolysis bullosa on the horizon? highlights the unprecedented pace of research and the growing global effort to repurpose existing drugs and develop gene‑based therapies. EB affects around 5,000 people in the UK and 500,000 worldwide, causing extremely fragile, blistering skin from birth or early childhood. Although currently incurable, new trials are offering families hope not previously seen.

DEBRA’s Director of Research, Sagair Hussain, features prominently in the article, outlining encouraging early results from repurposed anti‑inflammatory medicines, including apremilast and dupilumab, that have already improved wound healing, reduced pain and enhanced quality of life for some patients taking part in clinical trials. He also describes the ART‑EB programme, the world’s largest EB drug‑repurposing platform, which will test three drugs simultaneously to overcome the challenge of small patient numbers.

The feature also details advances in gene and cell therapies, including topical gene therapy Vyjuvek currently under NICE review, and the first FDA‑approved gene‑edited cell therapy for EB, Zevaskyn, approved in the US in 2025. Researchers emphasise that while a complete cure may still take time, the steps being taken now are vital first milestones on that journey.

A companion opinion piece, Access to rare disease treatment should not be a rarity, highlights the policy landscape shifting in the right direction. The UK government’s 2025 Rare Diseases Action Plan revealed that only 5% of rare diseases have an approved treatment — a statistic unchanged since 2017, underlining the pressing need for systemic reform.

However, new developments offer real promise. In November 2025, the MHRA announced it would “overhaul the rulebook” to speed up approvals for rare disease therapies, including treatments supported by limited but strong early‑stage evidence. NICE has also increased its cost‑effectiveness thresholds for the first time since 1999; a move expected to support approval of additional medicines each year, including therapies for rare diseases such as EB.

The opinion piece also highlights the innovative research underway and the barriers charities such as DEBRA work hard to overcome, including low patient numbers, complex licensing processes and commercial disincentives for companies to pursue approval of drugs for very small populations.

Together, both articles highlight why accelerating EB research and ensuring fair access to treatments must remain a national priority. For the EB community, these advances offer cautious optimism. Progress may not be instantaneous, but the direction of travel is clear: more treatments in development, more support for innovation, and a growing commitment across the UK health system to ensure that people living with EB are no longer left behind.